CV Therapeutics gets Ranexa tradename in the EU
This article was originally published in Scrip
CV Therapeutics will be able to market its novel angina treatment ranolazine as Ranexa in Europe following approval of the brand name by theEMEA. The product was granted approval last month for use as Latixa as an add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or are intolerant to first-line antianginal therapies. The Ranexa name is used in the product's first market, the US, allowing brand synergy across these two major markets, CV Therapeutics notes.
You may also be interested in...
A first look at the clinical data for Novavax’s COVID-19 vaccine suggests it can produce strong antibody responses while being well tolerated.
A couple of unexpected events for pimavanserin mean that Acadia will drop its development for major depressive disorder and have to wait a little longer to hear if it can launch the product for dementia-related psychosis, a large potential indication.
The US FDA has given the go-ahead for marketing of ViiV healthcare’s novel HIV drug just as the EMA removes the accelerated assessment status from its application there.